RecruitingPhase 3NCT04521881

Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults

Intramuscular Tranexamic Acid for the Treatment of Symptomatic Mild Traumatic Brain Injury in Older Adults: a Randomised, Double-blind, Placebo-controlled Trial

Sponsor

London School of Hygiene and Tropical Medicine

Enrollment

5,000 participants

Start Date

Apr 18, 2021

Study Type

INTERVENTIONAL

Conditions

Traumatic Brain Injury

Summary

Tranexamic acid (TXA) reduces head injury deaths. The CRASH-4 trial aims to assess the effects of early intramuscular TXA on intracranial haemorrhage, disability, death, and dementia in older adults with symptomatic mild head injury

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Tranexamic Acid 500 MG for people with traumatic brain injury. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 50 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTranexamic Acid 500 MG

given once as an intramuscular injection

Locations(2)

The Royal London Hospital

London, London, United Kingdom

St George's Hospital

London, London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04521881

Related Trials

Control Network Neuromodulation to Enhance Cognitive Training in Complex Traumatic Brain Injury

NCT052360105 locations

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

NCT059517772 locations